What are the effects of fezolinetant?

Fezolinetant is a new type of non-hormonal drug mainly used to treat moderate to severe vasomotor symptoms caused by menopause, especially hot flashes and other symptoms. It regulates the activity of the endocrine system and relieves symptoms related to menopause by acting on the neurokinin 3 (NK3) receptor. Fezonatant's mechanism of action is different from traditional hormone therapy drugs, making it an important non-hormonal treatment option.

One of the main effects of filazonatant is to relieve vasomotor symptoms, especially in menopausal women, where hot flashes are one of the most common symptoms. Hot flashes are characterized by sudden hot flashes, redness of the face and upper body, accompanied by symptoms such as sweating and rapid heartbeat. These symptoms seriously affect the quality of women's daily life. Traditional treatments often rely on hormone therapy, which is not suitable for all women, especially those at risk for breast, uterine, or other hormone-dependent diseases. As a non-hormonal treatment, filazonatant can relieve hot flashes and other vasomotor symptoms by blocking NK3 receptors, thus providing a safe treatment option for women.

The mechanism of action of filzonitant is closely related to the neurokinin3 (NK3) receptor. Neurokinin 3 is a neurotransmitter that is widely distributed in the brain and spinal cord and is related to multiple physiological processes such as temperature regulation, cardiovascular function, and emotional state. In menopausal women, the activity of NK3 receptors may be imbalanced, causing symptoms such as hot flashes. Fezonatant reduces the occurrence of these symptoms and helps relieve vasomotor problems caused by menopause by inhibiting the action of NK3 receptors.

Compared with traditional hormone replacement therapy, the advantage of filzonitant is that it does not rely on hormones to regulate hormone levels in the body. This provides a new treatment option for women who cannot receive hormone therapy.

Reference materials:https://www.astellas.com/content/dam/astellas-com/global/en/documents/veozah_usppi.pdf